^
    Back
    Association details:
    Biomarker:NPM1-ALK F1174C
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:TAE-684 (ALK inhibitor, LRRK2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    J Cancer Res Clin Oncol
    Title:

    Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma

    Excerpt:
    cDNA sequencing of ALK kinase domain revealed activating mutations—I1171T in Karpas299CR and F1174C in Karpas299CHR. The resistant cells displayed diminished sensitivity to structurally unrelated ALK inhibitors—crizotinib, CH5424802 and TAE684.
    DOI:
    10.1007/s00432-014-1589-3